Key Highlights
- Tozorakimab achieved its primary endpoint in AstraZeneca’s Phase III MIRANDA study for COPD treatment
- The therapeutic demonstrated reduced moderate-to-severe COPD exacerbations compared to placebo in former and current smokers
- Trial participants received 300mg doses of tozorakimab bi-weekly alongside standard treatment protocols
- March saw positive outcomes from two additional Phase III studies, OBERON and TITANIA
- Regulatory submission preparations underway with data presentation planned at future medical conference
AstraZeneca’s investigational COPD therapy tozorakimab has achieved another Phase III milestone, strengthening the clinical evidence supporting this experimental treatment.
The MIRANDA study demonstrated that tozorakimab achieved a statistically significant decrease in the annualized rate of moderate-to-severe COPD exacerbations when compared to placebo. These outcomes remained consistent across both the primary cohort of former smokers and the expanded population that included individuals who currently smoke.
Trial participants received either tozorakimab 300mg or placebo bi-weekly in addition to their established standard care regimens. The study focused on patients experiencing continued exacerbations while already receiving inhaled therapies.
The safety data aligned with previous clinical studies, with the medication demonstrating favorable tolerability overall.
Building on Previous Phase III Achievements
Tozorakimab has accumulated multiple successful Phase III outcomes. AstraZeneca reported favorable results in March from two separate Phase III studies — OBERON and TITANIA — which evaluated the therapy using a four-week administration schedule.
MIRANDA utilized a bi-weekly dosing regimen, providing AstraZeneca with comprehensive data across multiple dosing intervals.
The investigational drug represents a potentially first-in-class monoclonal antibody targeting interleukin-33, a protein that plays a role in inflammatory processes. This therapeutic mechanism differentiates it from currently available inhaled COPD medications.
Frank Sciurba, a professor at the University of Pittsburgh and chief investigator of the LUNA program, said the results “add to the growing body of evidence that indicates tozorakimab delivered meaningful clinical benefits for COPD patients who urgently need new treatment options.”
COPD impacts approximately 400 million individuals worldwide and ranks as the third leading cause of mortality globally. Over half of affected patients continue experiencing exacerbations despite adherence to standard inhaled treatment regimens — a treatment gap tozorakimab aims to address.
Regulatory Path Forward
AstraZeneca intends to file the MIRANDA study data with regulatory agencies. The pharmaceutical company will share detailed findings at a forthcoming medical conference, though specific timing and venue details remain to be announced.
Tozorakimab’s development extends beyond COPD, with Phase III evaluation ongoing for severe viral lower respiratory tract disease and Phase II assessment underway for asthma treatment.
The MIRANDA trial enrolled patients representing all blood eosinophil count levels and all degrees of lung function impairment, potentially expanding the eligible patient population for treatment.
AstraZeneca has yet to announce a definitive regulatory filing schedule.
